Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VH3810109 + cabotegravir
- Development stage
- Unknown
- Lead developer
- ViiV Healthcare
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous, Intramuscular
01
Overview
**VH3810109 + cabotegravir** is a combination investigational therapy for HIV consisting of VH3810109, a broadly neutralizing antibody (bNAb) targeting HIV-1, and cabotegravir, a long-acting small-molecule integrase strand transfer inhibitor (INSTI). VH3810109 (also known as N6LS or VH109) blocks HIV from entering healthy cells and activates immune cells to clear infected cells, while cabotegravir inhibits viral DNA integration, preventing replication. This combination is studied for long-acting HIV maintenance therapy, aiming to maintain viral suppression with infrequent dosing and reduce the burden of daily antiretroviral therapy. The main developer is ViiV Healthcare, and this regimen is currently in phase 2b clinical trials for virologically suppressed people with HIV, with evidence of efficacy and good tolerability in completed and ongoing studies[1][3][4].
- Other names
- VH3810109 + cabotegravir
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on VH3810109 + cabotegravir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VH3810109 + cabotegravir.